Skip to main content
Tianjin Ringpu Bio-Technology Co.,Ltd. logo

Tianjin Ringpu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 300119 ISIN · CNE100000TV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,284 across all filing types
Latest filing 2025-10-14 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300119

About Tianjin Ringpu Bio-Technology Co.,Ltd.

https://www.ringpu.com

Tianjin Ringpu Bio-Technology Co.,Ltd. is a high-tech enterprise specializing in the research, development, production, and sale of animal health products. The company offers a comprehensive portfolio that includes veterinary biological products, chemical drugs, feed additives, and pet health solutions. Its product range covers vaccines for poultry and livestock, as well as various pharmaceutical formulations such as injections, powders, and oral solutions. Ringpu Bio-Technology emphasizes innovation through its dedicated R&D centers, focusing on disease prevention and treatment to support the global animal husbandry industry. The company provides integrated health management services and high-quality veterinary medicines to ensure food safety and animal welfare.

Recent filings

Filing Released Lang Actions
第五届董事会第二十八次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by 瑞普生物股份有限公司 (Ruipu Bio Co., Ltd.). It details the convening of the fifth board's 28th (extraordinary) meeting, the attendance, the agenda item about joint investment with professional institutions, and the voting results. There is no financial data or report content, only a summary of board decisions and procedural compliance. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is short (940 characters), and it is not a report or financial statement. Therefore, the classification is MANG with high confidence.
2025-10-14 Chinese
第五届监事会第二十四次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at a supervisory board meeting of 瑞普生物股份有限公司 (Ruipu Bio Co., Ltd.). It details the meeting date, attendance, agenda item (approval of a joint investment with professional institutions), compliance with relevant laws and regulations, and voting results. The document is short (788 characters) and serves as an official notice of the supervisory board's decision rather than a full report or detailed financial disclosure. It does not contain financial statements, audit information, or management discussion. It is not a report publication announcement since it contains substantive content about the meeting resolution itself. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2025-10-14 Chinese
关于与专业投资机构共同投资的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from 瑞普生物股份有限公司 about a planned joint investment with professional investment institutions to establish a partnership enterprise focused on the pet industry chain. It includes extensive information about the investment structure, partners, capital contributions, governance, rights and obligations of partners, investment objectives, risks, and approvals by the board and supervisory committee. The document is not a financial report, earnings release, or regulatory certification. It is a formal announcement of a capital investment activity involving fund formation and capital commitment. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is too detailed and lengthy to be a simple report publication announcement or regulatory filing. The content fits best with the category of Capital/Financing Update (CAP), as it concerns fundraising, financing activities, and capital structure changes related to the establishment of a new investment fund partnership.
2025-10-14 Chinese
关于持股5%以上股东梁武持股在一致行动人之间内部转让计划完成的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of an internal share transfer among shareholders holding more than 5% of the company's shares. It details the transfer specifics, confirms no change in total shareholding percentage, and references compliance with relevant securities laws. There is no financial report, earnings data, or management discussion. The content fits the definition of a Major Shareholding Notification (MRQ), as it informs about changes in significant share ownership levels, even though the total ownership remains unchanged. The document length is short and focused on shareholding changes, not a full report or announcement of a report publication.
2025-10-13 Chinese
关于取得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of a new veterinary drug registration certificate. It details the approval of a new vaccine product by the Ministry of Agriculture and Rural Affairs, describing the product's features and market significance. The document is short (1105 characters) and does not contain financial data, financial statements, or regulatory filings related to financial performance. It is not a report, earnings release, or management discussion. It is an official announcement about a regulatory approval related to product registration, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. Given the nature of the announcement, it best fits under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-09-30 Chinese
中国银河证券股份有限公司关于瑞普生物股份有限公司变更部分募集资金用途的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from China Galaxy Securities regarding the change in the use of part of the funds raised by Ruipu Bio Co., Ltd. It includes extensive information about the original fundraising, usage of funds, reasons for changing the use of funds, new project details, feasibility, economic benefits, risks, and the sponsor's opinion. The document references regulatory rules related to fundraising and securities issuance, and it is signed by the sponsor representatives. The document length is 6630 characters, which is substantial and contains detailed substantive content about the fundraising and its changes, not merely an announcement or a certification. This fits the category of a Capital/Financing Update (CAP), as it provides an update on the company's fundraising and changes in the use of raised capital. It is not an Annual Report, Interim Report, or Audit Report, nor is it a simple announcement or voting result. Therefore, the appropriate classification is CAP with high confidence.
2025-09-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.